[{"id":"7d24d9e1-4dcb-42b7-a602-4f6bcfc0236d","acronym":"InCITe","url":"https://clinicaltrials.gov/study/NCT03971409","created_at":"2021-01-18T19:32:12.157Z","updated_at":"2024-07-02T16:35:04.267Z","phase":"Phase 2","brief_title":"Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer","source_id_and_acronym":"NCT03971409 - InCITe","lead_sponsor":"Hope Rugo, MD","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • Mektovi (binimetinib) • pegylated liposomal doxorubicin • Trodelvy (sacituzumab govitecan-hziy) • utomilumab (PF-05082566) • ivuxolimab (PF-04518600)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 07/08/2019","start_date":" 07/08/2019","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-05-13"},{"id":"66f13626-45a2-4288-b3f1-b38139944712","acronym":"NCI-2018-01118","url":"https://clinicaltrials.gov/study/NCT03217747","created_at":"2021-01-18T15:52:38.634Z","updated_at":"2024-07-02T16:35:12.950Z","phase":"Phase 1/2","brief_title":"Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies","source_id_and_acronym":"NCT03217747 - NCI-2018-01118","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab) • utomilumab (PF-05082566) • ivuxolimab (PF-04518600)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 173","initiation":"Initiation: 08/02/2017","start_date":" 08/02/2017","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-03-25"},{"id":"629a9570-5526-4e21-a561-e5d4879b487d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03390296","created_at":"2021-01-18T16:43:54.834Z","updated_at":"2024-07-02T16:35:38.199Z","phase":"Phase 1/2","brief_title":"OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT03390296","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Bavencio (avelumab) • azacitidine • Mylotarg (gemtuzumab ozogamicin) • Daurismo (glasdegib) • ivuxolimab (PF-04518600)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 02/04/2022","primary_completion_date":" 02/04/2022","study_txt":" Completion: 02/04/2022","study_completion_date":" 02/04/2022","last_update_posted":"2023-09-04"},{"id":"8f8790f1-33c5-4117-9b29-b1d397868ea7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03092856","created_at":"2021-01-18T15:14:12.812Z","updated_at":"2024-07-02T16:35:40.288Z","phase":"Phase 2","brief_title":"Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer","source_id_and_acronym":"NCT03092856","lead_sponsor":"University of Southern California","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e axitinib • ivuxolimab (PF-04518600)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 07/19/2017","start_date":" 07/19/2017","primary_txt":" Primary completion: 07/19/2024","primary_completion_date":" 07/19/2024","study_txt":" Completion: 07/19/2025","study_completion_date":" 07/19/2025","last_update_posted":"2023-08-11"}]